Smith & Nephew stock slips after lower analyst targets

Smith & Nephew stock lost support after Morgan Stanley cut its target to 1,158 pence and JPMorgan trimmed its view to 1,290 pence. The shares also sit near 10.63 GBP in London trading as investors weigh Q2 2026 revenue of USD 1.6 billion.

Smith & Nephew stock (GB0009223206) lost a little support after two large banks cut their views on the medical technology group. On September 2, 2026, Morgan Stanley downgraded the shares to Equal-weight and cut its target to 1,158 pence, while JPMorgan lowered its target to 1,290 pence, according to an Investing.com report on Morgan Stanley and a related market summary.

Lower targets hit sentiment

The same report said Morgan Stanley sees Smith & Nephew needing a medium-term rebase at its fiscal 2026 results in February 2027, which is a clear signal that analysts are now looking beyond the near-term quarter. JPMorgan's cut to 1,290 pence gives the stock a narrower cushion than before, with both banks reacting to the companys guidance reset.

Trading data in the same set of reports put the London-listed shares at 10.63 GBP on September 1, 2026, while a Reuters-linked director filing showed an average closing share price of 11.0265 GBP over the ten dealing days after the first-half results on August 4, 2026. That leaves the stock below the reference level used for the September 1 award calculation and gives the chart a clear comparison point.

Revenue still grows slowly

The latest half-year context remains mixed. A corporate-news summary updated on September 1, 2026 said Smith & Nephew generated USD 1.6 billion in revenue in Q2 2026, up 2.8 percent from Q2 2025 but below analyst expectations of USD 1.64 billion.

That gap matters because the same summary put underlying revenue growth at 1.6 percent year on year in Q2 2026. In Orthopaedics, revenue reached USD 614 million, slightly below USD 615 million a year earlier and under a consensus figure of USD 646 million.

CEO share awards matter

A Reuters-linked filing from September 1, 2026 said Deepak Nath received a Performance Share Plan award equal to 350 percent of salary, bringing total 2026 performance share awards to 650 percent of salary. The same filing also put the award price at 12.744 GBP per share and the performance-share count at 323,728 shares.

For investors, that combination of pay, price reference and first-half timing keeps attention on execution after a quarter that did not fully clear expectations. The operational picture is still growing, but only modestly, and the banks now price in less room for disappointment.

Product and market view

Smith & Nephew's product mix still centers on orthopaedics, wound care and sports medicine, and the latest numbers show why orthopaedics is the pressure point. Q2 2026 orthopaedics revenue of USD 614 million sat below the USD 646 million consensus figure cited in the same summary, making segment recovery more important than broad company language.

Stock closes near 10.63 GBP

Smith & Nephew stock was quoted at 10.63 GBP in London on September 1, 2026, while the same report set the September 1 reference price at 11.0265 GBP for the award calculation. The stock therefore traded below the share-price benchmark used in the recent filing.

Smith & Nephew stock facts

• Company: Smith & Nephew plc
• ISIN: GB0009223206
• Ticker: SN.L
• Trading venue: London Stock Exchange
• Price (as of September 1, 2026): 10.63 GBP
• Market capitalization: USD 12.04 billion (as of September 2, 2026)
• Sector / Industry: Health Care / Medical Devices
• Index membership: FTSE 100